Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement. Please note that this agreement limits use to scientific
  research. Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:52:36 ON 16 JAN 2008

=> file registry
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   0.21   0.21

FILE 'REGISTRY' ENTERED AT 07:52:53 ON 16 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JAN 2008 HIGHEST RN 960583-85-1
DICTIONARY FILE UPDATES: 14 JAN 2008 HIGHEST RN 960583-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10662183\10662183m.str





chain nodes :
1 2 3 4 14 15 16 17 23
ring nodes :
5 6 7 8 9 10
chain bonds :
1-2 2-3 2-4 8-14 14-15 15-16 16-17 17-23
ring bonds :
5-10 5-6 6-7 7-8 8-9 9-10
exact/norm bonds :
1-2 2-3 2-4 16-17 17-23
exact bonds :
8-14 14-15 15-16
normalized bonds :
5-10 5-6 6-7 7-8 8-9 9-10
isolated ring systems :
containing 5 :

G1:O,S,N

G2:CH2,Hy

Match level :

1:Atom 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
12:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 23:CLASS

L1   STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1   STR



G1 O,S,N

G2 CH2,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 07:53:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   65826 TO ITERATE

  3.0% PROCESSED   2000 ITERATIONS   1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 1301235 TO 1331805
PROJECTED ANSWERS: 314 TO   1002

L2   1 SEA SSS SAM L1

=> d scan

L2   1 ANSWERS   REGISTRY COPYRIGHT 2008 ACS on STN
IN   2-Thiophenecarboximidamide, N-[4-[2-(propylamino)ethyl]phenyl]-
MF   C16 H21 N3 S
CI   COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 full
FULL SEARCH INITIATED 07:53:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1313545 TO ITERATE

69.5% PROCESSED 913511 ITERATIONS 128 ANSWERS

76.1% PROCESSED 1000000 ITERATIONS 128 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.31

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1313545 TO 1313545
PROJECTED ANSWERS: 130 TO 206

L3 128 SEA SSS FUL L1

=> d scan

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Carbamic acid, [2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenoxy]ethyl][2-[4-[(imino-2-thienylmethyl)amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI)
MF C34 H47 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):95

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-cyclopentyl-3-[[(2-hydroxyethyl)methylamino]methyl]phenyl]-
MF C20 H27 N3 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-chloro-5-[(6-fluoro-1,2-benzisoxazol-3-yl)amino]phenyl]-
MF C18 H12 Cl F N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-fluoroethyl)amino]methyl]-4-phenoxyphenyl]-
MF C20 H20 F N3 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, N-(2,3-dihydro-1-methyl-1H-indol-5-yl)-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-
MF C24 H27 N5 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-4-phenoxyphenyl]-
MF C21 H23 N3 O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-2-methylphenyl]-, dihydrochloride (9CI)
MF C16 H21 N3 O S . 2 Cl H



L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[[2-[4-hydroxy-3,5-bis(1-methylethyl)phenyl]ethyl]amino]methyl]phenyl]-
MF C26 H33 N3 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, N-[4-(dimethylamino)phenyl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-
MF C23 H27 N5 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-4-(1-methylethoxy)phenyl]-
MF C18 H25 N3 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)amino]methyl]phenyl]-, dihydrochloride (9CI)
MF C14 H17 N3 O S . 2 Cl H



● 2 HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[[3-[4-hydroxy-3,5-bis(1-methylethyl)phenyl]propyl]amino]methyl]phenyl]-, dihydrochloride (9CI)
MF C27 H35 N3 O S . 2 Cl H



● 2 HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-[2-[[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methyl]amino]ethyl]phenyl]-
MF C27 H33 N3 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-(1-ethylpropoxy)-3-[[(2-hydroxyethyl)amino]methyl]phenyl]-
MF C19 H27 N3 O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-(1-ethylpropoxy)-3-[[(4-hydroxybutyl)amino]methyl]phenyl]-, dihydrochloride (9CI)
MF C21 H31 N3 O2 S . 2 Cl H



●2 HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-4-(methylsulfonyl)phenyl]-
MF C16 H21 N3 O3 S2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-[2-[(3-phenyl-2-propenyl)amino]ethyl]phenyl]-, monohydriodide (9CI)
MF C22 H23 N3 S . H I



● HI

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-methoxy-3-[[(2-methoxyethyl)amino]methyl]phenyl]-
MF C16 H21 N3 O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-(1-ethylpropoxy)-3-[[(2-hydroxyethyl)methylamino]methyl]phenyl]-, dihydrochloride (9CI)
MF C20 H29 N3 O2 S . 2 Cl H



●2 HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[bis(3-phenylpropyl)amino]methyl]-4-(methylthio)phenyl]-
MF C31 H35 N3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, N-(2,3-dihydro-1-methyl-1H-indol-5-yl)-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-, monohydrochloride (9CI)
MF C24 H27 N5 O S . Cl H



● HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-4-methoxyphenyl]-
MF C16 H21 N3 O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)amino]methyl]-4-methoxyphenyl]-, dihydrochloride (9CI)
MF C15 H19 N3 O2 S . 2 Cl H



● 2 HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[(butylamino)methyl]-4-(methylthio)phenyl]-
MF C17 H23 N3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, N-[4-(dimethylamino)phenyl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-, monohydrochloride (9CI)
MF C23 H27 N5 O S . Cl H



● HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2,2-difluoroethyl)amino]methyl]-4-methoxyphenyl]-, dihydrochloride (9CI)
MF C15 H17 F2 N3 O S . 2 Cl H



●2 HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[2-[butyl(hydroxymethyl)amino]ethyl]phenyl]-
MF C18 H25 N3 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[(ethylamino)methyl]-4-(methylthio)phenyl]-
MF C15 H19 N3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Butanamide, 4-[[4-[(imino-2-thienylmethyl)amino]phenyl]amino]-N-[4-[(methylsulfonyl)amino]phenyl]-
MF C22 H25 N5 O3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-[(methylpropylamino)methyl]phenyl]-
MF C16 H21 N3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-2-methylphenyl]-
MF C16 H21 N3 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)amino]methyl]-4-(methylthio)phenyl]-, dihydrochloride (9CI)
MF C15 H19 N3 O S2 . 2 Cl H



● 2 HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Butanamide, N-[4-(dimethylamino)phenyl]-4-[[4-[(imino-2-thienylmethyl)amino]phenyl]amino]-
MF C23 H27 N5 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboxamidimidamide, N-[4-[2-[[3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenyl]amino]ethyl]phenyl]- (9CI)
MF C24 H27 N3 O3 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboxamidimidamide, N-[3-[[hexyl(2-hydroxyethyl)amino]methyl]-4-methoxyphenyl]-
MF C21 H31 N3 O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Piperidinamine, 1-[5-(1,2-dithiolan-3-yl)-1-oxopentyl]-N-[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]- (9CI)
MF C25 H34 N4 O S3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2,2-difluoroethyl)amino]methyl]-4-methoxyphenyl]-
MF C15 H17 F2 N3 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(4-morpholinyl)phenyl]-
MF C25 H29 N5 O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-(cyclopentyloxy)-3-[[(2-hydroxyethyl)methylamino]methyl]phenyl]-
MF C20 H27 N3 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)amino]methyl]-2-methylphenyl]-, dihydrochloride (9CI)
MF C15 H19 N3 O S . 2 Cl H



●2 HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[[3-[4-hydroxy-3,5-bis(1-methylethyl)phenyl]propyl]amino]methyl]phenyl]-
MF C27 H35 N3 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-[2-[[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenoxy]ethyl]amino]ethyl]phenyl]-
MF C29 H39 N3 O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-(1-ethylpropoxy)-3-[[(4-hydroxybutyl)amino]methyl]phenyl]-
MF C21 H31 N3 O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-4-phenoxyphenyl]-, hydrochloride (9CI)
MF C21 H23 N3 O2 S . x Cl H





L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethyl]amino]methyl]phenyl]-
MF C28 H37 N3 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-[2-[[3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenyl]amino]ethyl]phenyl]-, dihydrochloride (9CI)
MF C24 H27 N3 O3 S . 2 Cl H





L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-(1-ethylpropoxy)-3-[[(2-hydroxyethyl)methylamino]methyl]phenyl]-
MF C20 H29 N3 O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-(1-ethylpropoxy)-3-[[[2-(1-piperazinyl)ethyl]amino]methyl]phenyl]-, tetrahydrochloride (9CI)
MF C23 H35 N5 O S . 4 Cl H



● 4 HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-4-(methylsulfinyl)phenyl]-
MF C16 H21 N3 O2 S2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-[2-[[(8-hydroxy-2-quinolinyl)methyl]amino]ethyl]phenyl]-
MF C23 H22 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboxamidamide, N-[3-[[(2-hydroxyethyl)amino]methyl]-4-methoxyphenyl]-
MF C15 H19 N3 O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Glycine, N-cyclopropyl-N-[[5-[(imino-2-thienylmethyl)amino]-2-methoxyphenyl]methyl]-, methyl ester
MF C19 H23 N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboxamidamide, N-[3-[[[2-(dimethylamino)ethyl]amino]methyl]-4-(methylthio)phenyl]-
MF C17 H24 N4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(4-morpholinyl)phenyl]-, monohydrochloride (9CI)
MF C25 H29 N5 O2 S . Cl H



● HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-fluoroethyl)amino]methyl]-4-phenoxyphenyl]-, dihydrochloride (9CI)
MF C20 H20 F N3 O S . 2 Cl H



●2 HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[hexyl(2-hydroxyethyl)amino]methyl]phenyl]-, bis(trifluoroacetate) (salt) (9CI)
MF C20 H29 N3 O S . 2 C2 H F3 O2

CM 1



CM 2



L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboxamidamide, N-[4-(methylthio)-3-[(propylamino)methyl]phenyl]-
MF C16 H21 N3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Carbamic acid, [3-[[4-(dimethylamino)phenyl]amino]-3-oxopropyl][[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI)
MF C28 H35 N5 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboxamidamide, N-[3-[[(2-fluoroethyl)amino]methyl]-4-methoxyphenyl]-, monohydrochloride (9CI)
MF C15 H18 F N3 O S . Cl H



● HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)(phenylmethyl)amino]methyl]phenyl]-
MF C21 H23 N3 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-4-(methylsulfonyl)phenyl]-, dihydrochloride (9CI)
MF C16 H21 N3 O3 S2 . 2 Cl H



●2 HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(phenylamino)phenyl]-
MF C27 H27 N5 O S

CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-[[(cyanomethyl)methylamino]methyl]phenyl]-
MF C15 H16 N4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)amino]methyl]-2-methylphenyl]-
MF C15 H19 N3 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-(methylthio)-3-[(3,3,3-trifluoropropyl)amino]phenyl]-
MF C15 H16 F3 N3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-[2-[(4-phenylbutyl)amino]ethyl]phenyl]-
MF C23 H27 N3 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-[2-[(3-phenyl-2-propenyl)amino]ethyl]phenyl]- (9CI)
MF C22 H23 N3 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-methoxyethyl)amino]methyl]phenyl]-
MF C15 H19 N3 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Carbamic acid, [1-[5-(1,2-dithiolan-3-yl)-1-oxopentyl]-4-piperidinyl][[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI)
MF C30 H42 N4 O3 S3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)propylamino]methyl]-4-(methylthio)phenyl]-
MF C18 H25 N3 O S2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(4-methyl-1-piperazinyl)phenyl]-
MF C26 H32 N6 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-(1-methylethoxy)-3-[[[2-(1-

piperazinyl)ethyl]amino]methyl]phenyl]-
MF C21 H31 N5 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[hexyl(2-hydroxyethyl)amino]methyl]-4-methoxyphenyl]-, dihydrochloride (9CI)
MF C21 H31 N3 O2 S . 2 Cl H



●2 HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[[3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]propyl]amino]methyl]phenyl]-
MF C29 H39 N3 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, N-[2,3-dihydro-1-(1-naphthalenylmethyl)-1H-indol-5-yl]-3-[[[5-[(imino-2-thienylmethyl)amino]-2-methoxyphenyl]methyl]amino]-

MF C35 H35 N5 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-(1-ethylpropoxy)-3-[[[2-(1-piperazinyl)ethyl]amino]methyl]phenyl]-
MF C23 H35 N5 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-(1-methylethoxy)-3-[[[2-(1-piperazinyl)ethyl]amino]methyl]phenyl]-, trihydrochloride (9CI)
MF C21 H31 N5 O S . 3 Cl H



●3 HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[[3-[3,5-bis(1,1-dimethylethyl)-4-

hydroxyphenyl]propyl]amino]methyl]phenyl]-, dihydrochloride (9CI)
MF C29 H39 N3 O S . 2 Cl H



● 2 HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboxamidamide, N-[4-[2-[[3-(4-hydroxy-3-methoxyphenyl)-2-propenyl]amino]ethyl]phenyl]-, (2E)-2-butenedioate (1:2) (salt) (9CI)
MF C23 H25 N3 O2 S . 2 C4 H4 O4

CM 1



CM 2

Double bond geometry as shown.



L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboxamidamide, N-[3-[[cyclopropyl(2-hydroxyethyl)amino]methyl]-4-methoxyphenyl]-
MF C18 H23 N3 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-aminoethyl)amino]methyl]-4-(1-ethylpropoxy)phenyl]-, trihydrochloride (9CI)
MF C19 H28 N4 O S . 3 Cl H



●3 HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)amino]methyl]-4-(methylthio)phenyl]-
MF C15 H19 N3 O S2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, N-[2,3-dihydro-1-(1-naphthalenylmethyl)-1H-indol-5-yl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-, monohydrochloride (9CI)
MF C34 H33 N5 O S . Cl H



● HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[hexyl(2-hydroxyethyl)amino]methyl]phenyl]-
MF C20 H29 N3 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[bis(2-hydroxyethyl)amino]methyl]-4-methoxyphenyl]-, dihydrochloride (9CI)
MF C17 H23 N3 O3 S . 2 Cl H



●2 HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(3-hydroxypropyl)amino]methyl]-4-(methylthio)phenyl]-
MF C16 H21 N3 O S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(4-methyl-1-piperazinyl)phenyl]-, monohydrochloride (9CI)
MF C26 H32 N6 O S . Cl H



L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[(diethylamino)methyl]-4-methoxyphenyl]-
MF C17 H23 N3 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]phenyl]-, dihydrochloride (9CI)
MF C15 H19 N3 O S . 2 Cl H



●2 HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)propylamino]methyl]-4-(methylthio)phenyl]-, dihydrochloride (9CI)
MF C18 H25 N3 O S2 . 2 Cl H



●2 HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-[2-[[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenoxy]ethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI)
MF C29 H39 N3 O2 S . Cl H



● HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-[(methyl-4-pentynylamino)methyl]phenyl]-(9CI)
MF C18 H21 N3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[2-[(2-hydroxyethyl)(phenylmethyl)amino]ethyl]phenyl]-
MF C22 H25 N3 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-4-(methylsulfinyl)phenyl]-, dihydrochloride (9CI)
MF C16 H21 N3 O2 S2 . 2 Cl H



● 2 HCl

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboximidamide, N-[4-[2-[[(2-methoxy-10H-phenothiazin-1-yl)methyl]amino]ethyl]phenyl]-
MF C27 H26 N4 O S2

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 128 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Thiophenecarboxamidamide, N-[4-[(methyl-2-propynylamino)methyl]phenyl]-
(9CI)
MF C16 H17 N3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 179.74 | 179.95

FILE 'CAPLUS' ENTERED AT 07:55:28 ON 16 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 16 Jan 2008 VOL 148 ISS 3
FILE LAST UPDATED: 14 Jan 2008 (20080114/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 11 L3

=> d l4 1-11 ibib abs hitstr

L4 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:319488 CAPLUS
DOCUMENT NUMBER: 138:337988
TITLE: Novel 2-[(iminomethyl)amino]phenyl derivatives useful as inhibitors of NO synthase and lipid peroxidation, their preparation, their application as medicines, and pharmaceutical compositions containing them
INVENTOR(S): Chabrier De Lassauniere, Pierre Etienne; Auvin, Serge; Bigg, Dennis; Auguet, Michel; Harnett, Jeremiah
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et D'Applications scientifiques (S.C.R.A.S.), Fr.
SOURCE: U.S. Pat. Appl. Publ., 78 pp., Cont.-in-part of U.S. Ser. No. 882,264.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003078420	A1	20030424	US 2002-191950	20020709
US 6809088	B2	20041026		
FR 2761066	A1	19980925	FR 1997-3528	19970324
FR 2761066	B1	20001124		
FR 2764889	A1	19981224	FR 1997-7701	19970620
FR 2764889	B1	20000901		

WO 9842696	A1	19981001	WO 1998-FR288		19980216
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
WO 9858934	A1	19981230	WO 1998-FR1250		19980615
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
US 6335445	B1	20020101	US 1999-456205		19991207
US 2002007062	A1	20020117	US 2001-882264		20010615
US 6630461	B2	20031007			
US 2005043397	A1	20050224	US 2004-898916		20040726
US 7122535	B2	20061017			
US 2005187272	A1	20050825	US 2005-105291		20050413
IN 2006DE01211	A	20071123	IN 2006-DE1211		20060517
PRIORITY APPLN. INFO.:			FR 1997-3528	A	19970324
			FR 1997-7701	A	19970620
			WO 1998-FR288	W	19980216
			WO 1998-FR1250	W	19980615
			US 1999-456205	A3	19991207
			US 2001-882264	A2	20010615
			IN 1998-DE599	A3	19980309
			US 1999-381749	A2	19990922
			US 2002-191950	A3	20020709
			US 2004-898916	A3	20040726

OTHER SOURCE(S): MARPAT 138:337988

GI



I

AB Title compds., e.g., N-[4-[[[[4-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl]amino]methyl]phenyl]thiophene-2-carboximidamide (I) are prepared The compds. are inhibitors of NO synthases, and are also antioxidants which inhibit lipid peroxidn. Approx. 70 examples are prepared I had IC50 for inhibiting rat neuronal NO synthase in vitro < 3.5 μM, and the IC50 for inhibiting rat cerebral lipid peroxidn. in vitro is < 30 μM.

IT 515815-31-3P, N-[3-[[[2-(4-Hydroxy-3,5-diisopropylphenyl)ethyl]amino]methyl]phenyl]thiophene-2-carboximidamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation and testing of 2-[(iminomethyl)amino]phenyl derivs. as inhibitors of NO synthase and lipid peroxidn.)

RN 515815-31-3 CAPLUS

CN 2-Thiophenecarboximidamide, N-[3-[[[2-[4-hydroxy-3,5-bis(1-methylethyl)phenyl]ethyl]amino]methyl]phenyl]- (CA INDEX NAME)



IT 515815-21-1P, N-[3-[[[3-(3,5-Di-tert-butyl-4-hydroxyphenyl)propyl]amino]methyl]phenyl]thiophene-2-carboximidamide dihydrochloride 515815-23-3P, N-[3-[[[2-(3,5-Di-tert-butyl-4-hydroxyphenyl)ethyl]amino]methyl]phenyl]thiophene-2-carboximidamide 515815-24-4P, N-[3-[[[3-(4-Hydroxy-3,5-diisopropylphenyl)propyl]amino]methyl]phenyl]thiophene-2-carboximidamide Dihydrochloride 515815-25-5P, N-[3-[[[2-(4-Hydroxy-3,5-diisopropylphenyl)ethyl]amino]methyl]phenyl]thiophene-2-carboximidamide Dihydrochloride 515815-27-7P, N-[3-[[[3-(3,5-Di-tert-butyl-4-hydroxyphenyl)propyl]amino]methyl]phenyl]thiophene-2-carboximidamide 515815-29-9P, N-[3-[[[3-(4-Hydroxy-3,5-diisopropylphenyl)propyl]amino]methyl]phenyl]thiophene-2-carboximidamide RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and testing of 2-[(iminomethyl)amino]phenyl derivs. as inhibitors of NO synthase and lipid peroxidn.)

RN 515815-21-1 CAPLUS

CN 2-Thiophenecarboximidamide, N-[3-[[[3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]propyl]amino]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)





RN 515815-23-3 CAPLUS

CN 2-Thiophenecarboximidamide, N-[3-[[[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethyl]amino]methyl]phenyl]- (CA INDEX NAME)



RN 515815-24-4 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[[3-[4-hydroxy-3,5-bis(1-methylethyl)phenyl]propyl]amino]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 515815-25-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[[2-[4-hydroxy-3,5-bis(1-methylethyl)phenyl]ethyl]amino]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 515815-27-7 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[[3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]propyl]amino]methyl]phenyl]- (CA INDEX NAME)



RN 515815-29-9 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[[3-[4-hydroxy-3,5-bis(1-methylethyl)phenyl]propyl]amino]methyl]phenyl]- (CA INDEX NAME)



L4 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:943608 CAPLUS
DOCUMENT NUMBER: 138:353784
TITLE: Novel inhibitors of neuronal nitric oxide synthase with potent antioxidant properties
AUTHOR(S): Auvin, Serge; Auguet, Michel; Navet, Edith; Harnett, Jeremiah J.; Viossat, Isabelle; Schulz, Jocelyne; Bigg, Dennis; Chabrier, Pierre-E.
CORPORATE SOURCE: Beaufour-Ipsen Research Laboratories, Department of Medicinal Chemistry, Institut Henri Beaufour, Les Ulis, 91966, Fr.
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(2), 209-212
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:353784
GI



I

AB A series of hybrid compds. possessing an nNOS pharmacophore linked to an antioxidant fragment has been synthesized. Among them, compound I·2HCl, a propofol derivative, displayed the greatest dual potencies against nNOS (IC50=0.12 μM) and lipid peroxidn. (IC50=0.4 μM) accompanied with e/nNOS selectivity (67.5). This shows that nNOS was able to accommodate very bulky groups such as di-tert-Bu or di-iso-Pr phenol in its active site.
IT 515815-21-1P 515815-23-3P 515815-24-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of novel inhibitors of neuronal nitric oxide synthase with potent antioxidant properties)
RN 515815-21-1 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[[3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]propyl]amino]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 515815-23-3 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethyl]amino]methyl]phenyl]- (CA INDEX NAME)



RN 515815-24-4 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[[3-[4-hydroxy-3,5-bis(1-methylethyl)phenyl]propyl]amino]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:185107 CAPLUS
DOCUMENT NUMBER: 136:247484
TITLE: Preparation of furan and thiophene amidine derivatives useful as inhibitors of nitric oxide synthase
INVENTOR(S): Chen, Deborah; Empfield, James; Mattes, Kenneth; Murray, Robert; Phillips, Eifion
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020511	A1	20020314	WO 2001-SE1868	20010830
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001082829	A5	20020322	AU 2001-82829	20010830

PRIORITY APPLN. INFO.:

GB 2000-21705	A	20000905
GB 2000-21706	A	20000905
SE 2001-2156	A	20010614
WO 2001-SE1868	W	20010830

OTHER SOURCE(S): MARPAT 136:247484
GI



I

AB Amidine derivs. [I; wherein Z = furan or thiophene ring (optionally substituted); X = (C1-C6)alkyl or CO; Y = O, S(O)a, or NR3 (wherein a = 0, 1, or 2; R3 = H, (C1-C6)alkyl, Ph, etc.); W = S(O)c (wherein c = 0, 1, or 2); R2 = H, (C1-C6)alkyl, Ph, etc.] were prepared Thus, a mixture of [3-(chloromethyl)-4-(methylsulfanyl)phenyl]-2-thiophenecarboximidamide hydrochloride, isopropylamine, and diisopropylethylamine in DMF was stirred at room temperature for 16 h to give 70% N-[3-[[isopropylamino]methyl]-4-[methylsulfanyl]phenyl]-2-thiophenecarboximidamide. The prepared compds. showed IC50 <10 μM for inhibition of neuronal nitric oxide synthase.

IT 403848-81-7P, N-[3-[[(2-Hydroxyethyl)(methyl)amino]methyl]-4-(methylsulfanyl)phenyl]-2-thiophenecarboximidamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of furan and thiophene amidine derivs. useful as inhibitors of nitric oxide synthase)

RN 403848-81-7 CAPLUS

CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-4-(methylthio)phenyl]- (CA INDEX NAME)



IT 403848-76-0P, N-[3-[(2,2-Difluoroethyl)amino]-4-(methylsulfanyl)phenyl]-2-thiophenecarboximidamide 403848-77-1P, N-[3-[(3,3,3-Trifluoropropyl)amino]-4-(methylsulfanyl)phenyl]-2-thiophenecarboximidamide 403848-80-6P, N-[3-[[(2-Hydroxyethyl)amino]methyl]-4-(methylsulfanyl)phenyl]-2-thiophenecarboximidamide dihydrochloride 403848-82-8P, N-[3-[[(2-Hydroxyethyl)(methyl)amino]methyl]-4-(methylsulfinyl)phenyl]-2-thiophenecarboximidamide dihydrochloride 403848-83-9P, N-[3-[[(2-Hydroxyethyl)(methyl)amino]methyl]-4-(methylsulfonyl)phenyl]-2-thiophenecarboximidamide dihydrochloride 403848-85-1P, N-[3-[(Ethylamino)methyl]-4-(methylsulfanyl)phenyl]-2-thiophenecarboximidamide 403848-86-2P, N-[3-[[(2-Hydroxyethyl)(ethyl)amino]methyl]-4-(methylsulfanyl)phenyl]-2-thiophenecarboximidamide 403848-87-3P 403848-90-8P, N-[3-[(n-Propylamino)methyl]-4-(methylsulfanyl)phenyl]-2-thiophenecarboximidamide 403848-91-9P, N-[3-[(n-Butylamino)methyl]-4-(methylsulfanyl)phenyl]-2-thiophenecarboximidamide 403848-93-1P, N-[3-[((S)-2-Hydroxy-1-propylamino)methyl]-4-(methylsulfanyl)phenyl]-2-thiophenecarboximidamide 403848-95-3P, N-[3-[[(3-Hydroxypropyl)amino]methyl]-4-(methylsulfanyl)phenyl]-2-thiophenecarboximidamide 403848-96-4P, N-[3-[[[2-(Dimethylamino)ethyl]amino]methyl]-4-(methylsulfanyl)phenyl]-2-thiophenecarboximidamide 403848-97-5P, N-[3-[[Bis(3-phenylpropyl)amino]methyl]-4-(methylsulfanyl)phenyl]-2-thiophenecarboximidamide 403848-99-7P, N-[3-[[(2,2-Difluoroethyl)amino]methyl]-4-(methylsulfanyl)phenyl]-2-thiophenecarboximidamide 403849-02-5P, N-[3-[[(2-Hydroxyethyl)amino]methyl]-4-(methylsulfanyl)phenyl]-2-thiophenecarboximidamide 403849-03-6P, N-[3-[[(2-Hydroxyethyl)(methyl)amino]methyl]-4-(methylsulfinyl)phenyl]-2-thiophenecarboximidamide 403849-04-7P, N-[3-[[(2-Hydroxyethyl)(methyl)amino]methyl]-4-(methylsulfonyl)phenyl]-2-thiophenecarboximidamide 403849-05-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of furan and thiophene amidine derivs. useful as inhibitors of nitric oxide synthase)

RN 403848-76-0 CAPLUS

CN 2-Thiophenecarboximidamide, N-[3-[(2,2-difluoroethyl)amino]-4-(methylthio)phenyl]- (CA INDEX NAME)



RN 403848-77-1 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-(methylthio)-3-[(3,3,3-trifluoropropyl)amino]phenyl]- (CA INDEX NAME)



RN 403848-80-6 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)amino]methyl]-4-(methylthio)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 403848-82-8 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-4-(methylsulfinyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 403848-83-9 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-4-(methylsulfonyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 403848-85-1 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[(ethylamino)methyl]-4-(methylthio)phenyl]- (CA INDEX NAME)



RN 403848-86-2 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[ethyl(2-hydroxyethyl)amino]methyl]-4-(methylthio)phenyl]- (CA INDEX NAME)



RN 403848-87-3 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)propylamino]methyl]-4-(methylthio)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 403848-90-8 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-(methylthio)-3-[(propylamino)methyl]phenyl]- (CA INDEX NAME)



RN 403848-91-9 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[(butylamino)methyl]-4-(methylthio)phenyl]- (CA INDEX NAME)



RN 403848-93-1 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[[(2S)-2-hydroxypropyl]amino]methyl]-4-(methylthio)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 403848-95-3 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(3-hydroxypropyl)amino]methyl]-4-(methylthio)phenyl]- (CA INDEX NAME)



RN 403848-96-4 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[[2-(dimethylamino)ethyl]amino]methyl]-4-(methylthio)phenyl]- (CA INDEX NAME)



RN 403848-97-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[bis(3-phenylpropyl)amino]methyl]-4-(methylthio)phenyl]- (CA INDEX NAME)



RN 403848-99-7 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2,2-difluoroethyl)amino]methyl]-4-(methylthio)phenyl]- (CA INDEX NAME)



RN 403849-02-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)amino]methyl]-4-(methylthio)phenyl]- (CA INDEX NAME)



RN 403849-03-6 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-4-(methylsulfinyl)phenyl]- (CA INDEX NAME)



RN 403849-04-7 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 403849-05-8 CAPLUS
CN 2,5-Thiophenedicarboximidamide, N-[3-[[(2-hydroxyethyl)propylamino]methyl]-4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:107089 CAPLUS
DOCUMENT NUMBER: 136:167182
TITLE: Novel cdc25 phosphatase inhibitors
INVENTOR(S): Prevost, Gregoire; Brezak Pannetier, Marie-Christine; Galcera Contour, Marie-Odile; Thurieau, Christophe; Goubin-Grammatica, Francoise; Ducommun, Bernard; Lanco, Christophe
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (SCRAS), Fr.
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002009686	A2	20020207	WO 2001-FR2443	20010726
WO 2002009686	A3	20031009		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2812198	A1	20020201	FR 2000-9900	20000728
CA 2417262	A1	20020207	CA 2001-2417262	20010726
EP 1370255	A2	20031217	EP 2001-960837	20010726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012824	A	20040210	BR 2001-12824	20010726
HU 2003003828	A2	20040301	HU 2003-3828	20010726
HU 2003003828	A3	20071029		
JP 2004506618	T	20040304	JP 2002-515239	20010726
NZ 523739	A	20050930	NZ 2001-523739	20010726
EP 1602368	A2	20051207	EP 2005-18614	20010726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
RU 2285521	C2	20061020	RU 2003-105689	20010726
NO 2003000421	A	20030319	NO 2003-421	20030127
US 2004034103	A1	20040219	US 2003-343171	20030127
US 7196084	B2	20070327		

MX 2003PA00860	A	20030606	MX 2003-PA860		20030128
US 2006154933	A1	20060713	US 2006-350692		20060209
US 2006235027	A1	20061019	US 2006-410659		20060425
AU 2006233164	A1	20061109	AU 2006-233164		20061024
PRIORITY APPLN. INFO.:			FR 2000-9900	A	20000728
			EP 2001-960837	A3	20010726
			WO 2001-FR2443	W	20010726
			US 2003-343171	A3	20030127

OTHER SOURCE(S): MARPAT 136:167182

AB Novel cdc25 phosphatase inhibitors, particularly cdc25-C inhibitors, A-B-N(W)-X-Y [A = (un)substituted Ph, 2-naphthyl; B = CO, NHCO(CH2)n, (CH2)p; n = 0-3; p = 0, 1; W = H, alkyl; X = (CH2)q, (CH2)qNH, CO(CH2)r; q = 1-6; r = 0-6; N(W)X = (un)substituted diazacycloalkyl; Y = (un)substituted Ph] were prepared Thus, 4-O2NC6H4CH2CH2NMeCH2C6H3(NMe2)OH-5,2 was obtained from 4-O2NC6H4CH2CH2NHMe and 5,2-Me2N(HO)C6H3CHO by reductive alkylation. This compound had an IC50 < 100μM for inhibition of recombinant cdc25-C phosphatase and for inhibition of Mia-Paca2 cell proliferation.

IT 262614-22-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenol and naphthol derivs. as inhibitors of cdc25-C phosphatase)

RN 262614-22-2 CAPLUS

CN Propanamide, N-[4-(dimethylamino)phenyl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]- (CA INDEX NAME)



L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:851122 CAPLUS

DOCUMENT NUMBER: 135:371759

TITLE: Preparation of N-imidazolylphenyl-5,6-dihydrobenzo[h]quinazolin-4-amines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders

INVENTOR(S): Yamada, Akira; Spears, Glen; Hayashida, Hisashi; Tomishima, Masaki; Ito, Kiyotaka; Imanishi, Masashi

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 154 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087845	A2	20011122	WO 2001-JP4002	20010514
WO 2001087845	A3	20020829		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU,

LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001056728	A5	20011126	AU 2001-56728		20010514
US 2003176454	A1	20030918	US 2002-258582		20021101
PRIORITY APPLN. INFO.:			AU 2000-7501	A	20000515
			AU 2000-1955	A	20001207
			WO 2001-JP4002	W	20010514

OTHER SOURCE(S): MARPAT 135:371759
GI



II

AB Title compds. AMQNHZ [I; wherein A = H, (un)substituted, unsatd., N-containing heterocyclic group, or C(NH)NHR; R = (un)substituted aryl or heterocyclic group; M = (CH2)n, (CH2)nO(CH2)m, or (CH2)nNH(CH2)m; n and m = independently 0-2; Q = (un)substituted cycloalkylene group, arylene, or divalent heterocyclic group; Z = (un)substituted, unsatd., mono-, di-, tri-, or tetra-cyclic, N-containing heterocyclic group which may contain addnl. N, O, and S atoms as the ring member(s), e.g. indeno[1,2,3-de]phthalazinyl or 5,6-dihydrobenzo[h]quinazolinyl; and the prodrugs or pharmaceutically acceptable salts thereof] were prepared For example, a mixture of 4-chloro-5,6-dihydrobenzo[h]quinazoline, 3-(1,2-dimethyl-1H-imidazol-5-yl)aniline, and 1,3-dimethyl-2-imidazolidinone was heated for an hour at 200°C, cooled, treated with 1N aqueous NaOH and water, and worked up to give II. I are 5-hydroxytryptamine (5-HT) antagonists useful for the prevention and/or treatment of central nervous system (CNS) disorders, such as anxiety, depression, obsessive compulsive disorders, migraine, anorexia, Alzheimer's disease, sleep disorders, bulimia, panic attacks, withdrawal from drug abuse, schizophrenia, and disorders associated with spinal trauma and/or head injury (no data).

IT 374556-21-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders)

RN 374556-21-5 CAPLUS

CN 2-Thiophenecarboximidamide, N-[3-chloro-5-[(6-fluoro-1,2-benzisoxazol-3-yl)amino]phenyl]- (CA INDEX NAME)



L4 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:693317 CAPLUS
DOCUMENT NUMBER: 135:257089
TITLE: Preparation and use of novel lipoic acid heterocyclic or benzene derivatives as medicines
INVENTOR(S): Harnett, Jeremiah; Auguet, Michel
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.), Fr.
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068643	A2	20010920	WO 2001-FR764	20010315
WO 2001068643	A3	20020606		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2806409	A1	20010921	FR 2000-3355	20000316
FR 2806409	B1	20020419		
CA 2402898	A1	20010920	CA 2001-2402898	20010315
EP 1265891	A2	20021218	EP 2001-917143	20010315
EP 1265891	B1	20041229		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003527391	T	20030916	JP 2001-567734	20010315
HU 2003003127	A2	20040301	HU 2003-3127	20010315
AT 286050	T	20050115	AT 2001-917143	20010315
PT 1265891	T	20050429	PT 2001-917143	20010315
ES 2234825	T3	20050701	ES 2001-1917143	20010315
RU 2260005	C2	20050910	RU 2002-127729	20010315
US 2003105107	A1	20030605	US 2002-221432	20020910
US 6936715	B2	20050830		
US 2005227991	A1	20051013	US 2005-147561	20050608
US 7285664	B2	20071023		

PRIORITY APPLN. INFO.:
FR 2000-3355 A 20000316
FR 2000-12007 A 20000921
WO 2001-FR764 W 20010315
US 2002-221432 A3 20020910

OTHER SOURCE(S): CASREACT 135:257089; MARPAT 135:257089
GI



I



II



III

AB The invention concerns novel heterocyclic or benzene derivs., e.g., I [A = N:C(A')NH2; A' = linear or branched C1-6-alkyl, 5-6 membered aryl or heterocycle; B1, B2 = (CH2)n; P = (CH2)g, R6-substituted phenylene; XY = O(CH2)r, NR3(CH2)r, CO(CH2)r, CONR3(CH2)2, NR4CO(CH2)r, NR3CONR4(CH2)r; X'Y' = (CH2)r, (CH2)rO(CH2)r, (CH2)rNR3(CH2)r,(CH2)rCO(CH2)r, (CH2)rCONR3(CH2)r, (CH2)rNR4CO(CH2)r,(CH2)NR3rCONR4(CH2)r; Z1, Z2 = 5-6 membered aromatic heterocyclic, 4-7 non-aromatic heterocyclic; Ph, C6H5R5; R1, R2 = H, linear or branched C1-6-alkyl; R3, R4 = H, alkyl, alkoxycarbonyl, aralkoxycarbonyl; R5 = H, linear or branched C1-6-alkyl, (CH2)m-Q; Q = H, OH, CN, NH2, alkoxy, (di)alkylamino; R6 = linear or branched C1-6-alkyl, (CH2)n-Q'; Q' = halogen, CF3, OH, NH2, CN, alkoxycarbonyl, aralkoxycarbonyl, alkoxy, alkylthio, (di)alkylamino; n = 0 - 6; g = 0 - 6; r = 0 - 6; m = 0 - 6] and II, or their pharmaceutically acceptable salts, comprising a lateral chain derived from lipoic acid, having an activity inhibiting NO-synthase enzymes producing NO nitrogen monoxide and/or are agents enabling regeneration of antioxidants or entities trapping reactive oxygen species (ROS) and intervening more generally in the redox status of thiol groups, methods for preparing them, pharmaceutical compns. containing them
and their therapeutic use, particularly their use as NO-synthase inhibitors and/or as agents involved more generally in the redox status of thiol groups. Thus, thiophenecarboximidamide III·HCl was prepared from DL-thioctic acid, HS(CH2)2CH(SH)(CH2)4CO2H, via amidation with N-(p-nitrophenyl)piperazine, nitro group reduction and condensation with S-methyl-2-thiophenethiocarboximide hydroiodide. III·HCl was tested for inhibition of NO synthase from rat cerebellum (CI50 = 4.5 μM) and for its effect on oxidative stress induced by glutamate on HT-22 cell cultures (CE50 = 4 μM).

IT 361345-27-9P 361345-28-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and use of novel lipoic acid heterocyclic or benzene derivs. with NO synthase inhibitory activity as medicinals)

RN 361345-27-9 CAPLUS

CN Carbamic acid, [1-[5-(1,2-dithiolan-3-yl)-1-oxopentyl]-4-piperidinyl][[3-

[(imino-2-thienylmethyl)amino]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361345-28-0 CAPLUS
CN 4-Piperidinamine, 1-[5-(1,2-dithiolan-3-yl)-1-oxopentyl]-N-[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:472696 CAPLUS
DOCUMENT NUMBER: 135:76783
TITLE: Preparation of furan and thiophene amidine derivatives useful as inhibitors of nitric oxide synthase
INVENTOR(S): Chen, Deborah; Empfield, James; Macdonald, James; Mattes, Kenneth; Murray, Robert; Phillips, Eifion; Schmitthenner, Hans
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001046171	A1	20010628	WO 2000-SE2540	20001214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002137750	A1	20020926	US 2001-763838	20010227
PRIORITY APPLN. INFO.:			SE 1999-4677 A	19991220
			WO 1999-SE2540 W	20001214

OTHER SOURCE(S): CASREACT 135:76783; MARPAT 135:76783
GI



I



II



III

AB There are provided novel compds. (shown as I; e.g. N-[3-[[(2R)-2-(hydroxymethyl)pyrrolidinyl]methyl]-4-methoxyphenyl]thiophene-2-carboximidamide) and optical isomers, racemates and tautomers thereof and pharmaceutically acceptable salts thereof, together with processes for their preparation, compns. containing them and their use in therapy. The compds.
are inhibitors (no data) of the enzyme nitric oxide synthase, especially the neuronal isoform of nitric oxide synthase. In I, Z = furan or thiophene ring, optionally substituted by ≥1 halogen, trifluoromethyl, C1-6 alkyl, C1-6 alkoxy, hydroxy, amino, S(O)qR4, CO2R5 and CONR6R7; X = C1-6 alkyl; Y = O, S(O)n or NR3; n and q independently = 0-2; R1 = H, halogen, C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkoxy-O-R8, C1-6 alkoxy-NR9R10 or O-phenyl; said Ph being optionally substituted by ≥1 halogen, trifluoromethyl, C1-6 alkyl, C1-6 alkoxy, hydroxy and amino; R2 represents C1-6 alkyl-O-R11 or C1-6 alkyl-NR12R13; R3 = H, C1-6 alkyl, C2-7 alkanoyl, C1-6 alkyl-O-R, C1-6 alkyl-NR15R16 or CH2-phenyl; said Ph being optionally substituted by ≥1 halogen, trifluoromethyl, C1-6 alkyl, C1-6 alkoxy, hydroxy and amino; or the group NR2R3 represents azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, or piperazinyl optionally 4-substituted by C1-6 alkyl; each of said azacyclic rings being substituted by O-R17, NR18R19, C1-6 alkyl-O-R17 or C1-6 alkyl-NR18R19 or, when Y = NR3, the groups X and R3 are joined together such that the group X-N-R3 represents a saturated 4 to 7 membered azacyclic ring; R4-R19 independently = H or C1-6 alkyl; or the groups NR9R10, NR12R13, NR15R16 and NR18R19 independently = azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl; or piperazinyl optionally 4-substituted by C1-6 alkyl. The claimed compds. are claimed to be useful for treating, or reducing the risk of hypoxia, stroke, Parkinson's disease, ischemia, neurodegenerative conditions, schizophrenia, anxiety, pain or migraine. Claimed methods of preparing I comprise (a) reacting II or a salt thereof with HN:CZL or a salt thereof (L = a leaving group); or (b) reacting III or a salt thereof (L1 = leaving group) with HYR2 or a salt thereof; or (c) preparing I (X = CH2) by reduction of a corresponding compound wherein X = C(O). 43 Example prepns. are given, but all are for thiophene derivs.

IT 346732-52-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of furan and thiophene amidine derivs. useful as inhibitors of nitric oxide synthase)

RN 346732-52-3 CAPLUS

CN Glycine, N-cyclopropyl-N-[[5-[(imino-2-thienylmethyl)amino]-2-methoxyphenyl]methyl]-, methyl ester (CA INDEX NAME)



IT 346731-65-5P 346731-67-7P 346731-69-9P
346731-70-2P 346731-71-3P 346731-72-4P
346731-73-5P 346731-74-6P 346731-75-7P
346731-76-8P 346731-77-9P 346731-78-0P
346731-79-1P 346731-80-4P 346731-81-5P
346731-82-6P 346731-84-8P 346731-87-1P
346731-88-2P 346731-89-3P 346731-92-8P
346731-95-1P 346731-96-2P 346731-97-3P
346731-99-5P 346732-03-4P 346732-04-5P
346732-05-6P 346732-28-3P 346732-34-1P
346732-40-9P 346732-43-2P 346732-46-5P
346732-49-8P 346732-53-4P 346732-54-5P
346732-55-6P 346732-56-7P 346732-57-8P
346732-58-9P 346732-59-0P 346732-60-3P
346732-67-0P 346732-70-5P 346732-73-8P
346732-78-3P 346732-79-4P 346732-81-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of furan and thiophene amidine derivs. useful as inhibitors of nitric oxide synthase)

RN 346731-65-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-4-methoxyphenyl]- (CA INDEX NAME)



RN 346731-67-7 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]phenyl]- (CA INDEX NAME)



RN 346731-69-9 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[hexyl(2-hydroxyethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 346731-70-2 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)amino]methyl]-4-methoxyphenyl]- (CA INDEX NAME)



RN 346731-71-3 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-methoxy-3-[[(2-methoxyethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 346731-72-4 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[bis(2-hydroxyethyl)amino]methyl]-4-methoxyphenyl]- (CA INDEX NAME)



RN 346731-73-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[cyclopropyl(2-hydroxyethyl)amino]methyl]-4-methoxyphenyl]- (CA INDEX NAME)



RN 346731-74-6 CAPLUS

CN 2-Thiophenecarboximidamide, N-[4-(1-ethylpropoxy)-3-[[(2-hydroxyethyl)methylamino]methyl]phenyl]- (CA INDEX NAME)



RN 346731-75-7 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-(1-ethylpropoxy)-3-[[(2-hydroxyethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 346731-76-8 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-aminoethyl)amino]methyl]-4-(1-ethylpropoxy)phenyl]- (CA INDEX NAME)



RN 346731-77-9 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-(1-ethylpropoxy)-3-[[[2-(1-piperazinyl)ethyl]amino]methyl]phenyl]- (CA INDEX NAME)



RN 346731-78-0 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-(1-ethylpropoxy)-3-[[(4-hydroxybutyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 346731-79-1 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-4-(1-methylethoxy)phenyl]- (CA INDEX NAME)



RN 346731-80-4 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(4-hydroxybutyl)amino]methyl]-4-(1-methylethoxy)phenyl]- (CA INDEX NAME)



RN 346731-81-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-(1-methylethoxy)-3-[[[2-(1-piperazinyl)ethyl]amino]methyl]phenyl]- (CA INDEX NAME)



RN 346731-82-6 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-(cyclopentyloxy)-3-[[(2-hydroxyethyl)methylamino]methyl]phenyl]- (CA INDEX NAME)



RN 346731-84-8 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-4-phenoxyphenyl]- (CA INDEX NAME)



RN 346731-87-1 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 346731-88-2 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-methoxyethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 346731-89-3 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[hexyl(2-hydroxyethyl)amino]methyl]-4-methoxyphenyl]- (CA INDEX NAME)



RN 346731-92-8 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-cyclopentyl-3-[[(2-hydroxyethyl)methylamino]methyl]phenyl]- (CA INDEX NAME)



RN 346731-95-1 CAPLUS
CN 3-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-4-methoxyphenyl]- (CA INDEX NAME)



RN 346731-96-2 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)amino]methyl]-2-methylphenyl]- (CA INDEX NAME)



RN 346731-97-3 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-2-methylphenyl]- (CA INDEX NAME)



RN 346731-99-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[5-[[(2-hydroxyethyl)methylamino]methyl]-2-methylphenyl]- (CA INDEX NAME)



RN 346732-03-4 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[2-[(2-hydroxyethyl)(phenylmethyl)amino]ethyl]phenyl]- (CA INDEX NAME)



RN 346732-04-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)(phenylmethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 346732-05-6 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[2-[butyl(hydroxymethyl)amino]ethyl]phenyl]- (CA INDEX NAME)



RN 346732-28-3 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-4-methoxyphenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 346732-34-1 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 346732-40-9 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[hexyl(2-hydroxyethyl)amino]methyl]phenyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 346731-69-9
CMF C20 H29 N3 O S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 346732-43-2 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)amino]methyl]-4-methoxyphenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 346732-46-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-methoxy-3-[[(2-methoxyethyl)amino]methyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 346732-49-8 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[bis(2-hydroxyethyl)amino]methyl]-4-methoxyphenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 346732-53-4 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-(1-ethylpropoxy)-3-[[(2-hydroxyethyl)methylamino]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 346732-54-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-(1-ethylpropoxy)-3-[[(2-hydroxyethyl)amino]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 346732-55-6 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-aminoethyl)amino]methyl]-4-(1-ethylpropoxy)phenyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 346732-56-7 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-(1-ethylpropoxy)-3-[[[2-(1-piperazinyl)ethyl]amino]methyl]phenyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)



●4 HCl

RN 346732-57-8 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-(1-ethylpropoxy)-3-[[(4-hydroxybutyl)amino]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 346732-58-9 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(4-hydroxybutyl)amino]methyl]-4-(1-methylethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 346732-59-0 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-(1-methylethoxy)-3-[[[2-(1-piperazinyl)ethyl]amino]methyl]phenyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 346732-60-3 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-4-phenoxyphenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 346732-67-0 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)amino]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 346732-70-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-methoxyethyl)amino]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 346732-73-8 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[hexyl(2-hydroxyethyl)amino]methyl]-4-methoxyphenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 346732-78-3 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)amino]methyl]-2-methylphenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 346732-79-4 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-hydroxyethyl)methylamino]methyl]-2-methylphenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 346732-81-8 CAPLUS
CN 2-Thiophenecarboximidamide, N-[5-[[(2-hydroxyethyl)methylamino]methyl]-2-methylphenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:472695 CAPLUS
DOCUMENT NUMBER: 135:76782
TITLE: Amidine derivatives which are inhibitors of nitric oxide synthase
INVENTOR(S): Mattes, Kenneth; Murray, Robert; Phillips, Eifion; Schmitthenner, Hans
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001046170	A1	20010628	WO 2000-SE2539	20001214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002137736	A1	20020926	US 2001-763835	20010227
PRIORITY APPLN. INFO.:			SE 1999-4676 A	19991220
			WO 2000-SE2539 W	20001214

OTHER SOURCE(S): MARPAT 135:76782
GI



I

AB Amidines I [Z = (un)substituted furyl or thienyl; R1 = H, alkyl, alkoxyalkyl, aminoalkyl, etc.; X = alkyl; NR2R3 = NH2, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, etc.] were prepared and showed IC50 values of <10 μM for inhibition of neuronal nitric oxide synthase. Thus, N-[4-methoxy-3-[(methylamino)methyl]phenyl]-2-thiophenecarboximidamide dihydrochloride was prepared in 3 steps starting from 2-methoxy-5-nitrobenzaldehyde and MeNH2 and proceeding via 4-methoxy-3-[(methylamino)methyl]aniline hydrochloride.

IT 346705-39-3P 346705-41-7P 346705-42-8P
346705-44-0P 346705-55-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amidine inhibitors of nitric oxide synthase)

RN 346705-39-3 CAPLUS

CN 2-Thiophenecarboximidamide, N-[3-[[(2-fluoroethyl)amino]methyl]-4-methoxyphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 346705-41-7 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2,2-difluoroethyl)amino]methyl]-4-methoxyphenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 346705-42-8 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-methoxy-3-[[(2,2,2-trifluoroethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 346705-44-0 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[(diethylamino)methyl]-4-methoxyphenyl]- (CA INDEX NAME)



RN 346705-55-3 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[[(2-fluoroethyl)amino]methyl]-4-phenoxyphenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:380573 CAPLUS
DOCUMENT NUMBER: 134:366792
TITLE: Preparation of novel amidine derivatives as NO synthase and/or monoamine oxydase inhibitors
INVENTOR(S): Chabrier De Lassauniere, Pierre-Etienne; Harnett, Jeremiah
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.), Fr.
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001036407	A1	20010525	WO 2000-FR3168	20001115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2801053	A1	20010518	FR 1999-14334	19991116
FR 2801053	B1	20040625		
CA 2391598	A1	20010525	CA 2000-2391598	20001115
EP 1233957	A1	20020828	EP 2000-979732	20001115
EP 1233957	B1	20060222		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2002003557	A2	20030328	HU 2002-3557	20001115
JP 2003514811	T	20030422	JP 2001-538896	20001115
AT 318265	T	20060315	AT 2000-979732	20001115
RU 2272807	C2	20060327	RU 2002-115868	20001115
ES 2258984	T3	20060916	ES 2000-979732	20001115
US 6770669	B1	20040803	US 2002-111434	20020423
US 2004225008	A1	20041111	US 2004-834654	20040429
US 7019025	B2	20060328		

PRIORITY APPLN. INFO.:			
	FR 1999-14334	A	19991116
	WO 2000-FR3168	W	20001115

OTHER SOURCE(S): MARPAT 134:366792

AB Amidine derivs., useful for preparing a medicine designed to inhibit NO synthases and/or monoamine oxydases, were prepared Thus, N'-(4-{[methyl(2-propynyl)amino]methyl}phenyl)-2-thiophenecarboximidamide; N'-(4-{[methyl(cyanomethyl)amino]methyl}phenyl)-2-thiophenecarboximidamide; N'-(4-{[methyl(propyl)amino]methyl}phenyl)-2-thiophenecarboximidamide; N'-(4-{[methyl(3-cyanoethyl)amino]methyl}phenyl)-2-thiophenecarboximidamide; and N'-(4-{[methyl(4-pentynyl)amino]methyl}phenyl)-2-thiophenecarboximidamide were prepared

IT 340293-49-4P 340293-50-7P 340293-51-8P 340293-52-9P 340293-53-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiophenecarboximidamides as NO synthase and/or monoamine oxydase inhibitors)

RN 340293-49-4 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[(methyl-2-propynylamino)methyl]phenyl]-(9CI) (CA INDEX NAME)



RN 340293-50-7 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[[(cyanomethyl)methylamino]methyl]phenyl]- (CA INDEX NAME)



RN 340293-51-8 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[(methylpropylamino)methyl]phenyl]- (CA INDEX NAME)



RN 340293-52-9 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[[(2-cyanoethyl)methylamino]methyl]phenyl]- (CA INDEX NAME)



RN 340293-53-0 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[(methyl-4-pentynylamino)methyl]phenyl]-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:210152 CAPLUS
DOCUMENT NUMBER: 132:251068
TITLE: Preparation of N-phenylthiopheneimidamides and analogs as NO synthase inhibitors and oxygen scavengers
INVENTOR(S): Bigg, Dennis; Chabrier De Lassauniere, Pierre-Etienne; Auvin, Serge; Harnett, Jeremiah; Ulibarri, Gerard
PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'Applications Scientifiques (S.C.R.A.S, Fr.
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000017191	A2	20000330	WO 1999-FR2251	19990922
WO 2000017191	A3	20001026		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2784678	A1	20000421	FR 1998-11867	19980923
FR 2784678	B1	20021129		
CA 2344223	A1	20000330	CA 1999-2344223	19990922
AU 9956315	A	20000410	AU 1999-56315	19990922
AU 759958	B2	20030501		
BR 9913899	A	20010703	BR 1999-13899	19990922
EP 1115720	A2	20010718	EP 1999-943025	19990922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

HU 2001004013	A2	20020429	HU 2001-4013		19990922
HU 2001004013	A3	20030128			
JP 2003517444	T	20030527	JP 2000-574100		19990922
NZ 511188	A	20030829	NZ 1999-511188		19990922
RU 2230742	C2	20040620	RU 2001-111023		19990922
US 6482822	B1	20021119	US 2001-787466		20010316
NO 2001001478	A	20010322	NO 2001-1478		20010322
MX 2001PA03006	A	20010910	MX 2001-PA3006		20010322
ZA 2001003206	A	20020719	ZA 2001-3206		20010419
IN 2001MN00427	A	20050909	IN 2001-MN427		20010419
HK 1043365	A1	20050107	HK 2002-105058		20020708
US 6620840	B1	20030916	US 2002-255849		20020926
US 2004097494	A1	20040520	US 2003-612646		20030701
US 6809090	B2	20041026			
US 2005027009	A1	20050203	US 2004-895578		20040721
US 2005197329	A1	20050908	US 2005-114803		20050426
US 7186752	B2	20070306			
IN 2005MN00576	A	20051104	IN 2005-MN576		20050607
PRIORITY APPLN. INFO.:			FR 1998-11867	A	19980923
			WO 1999-FR2251	W	19990922
			US 2001-787466	A3	20010316
			IN 2001-MN427	A3	20010419
			US 2002-255849	A3	20020926
			US 2003-612646	A3	20030701
			US 2004-895578	A3	20040721

OTHER SOURCE(S): MARPAT 132:251068

GI



II

AB R1Z1Z2ZNCRNH2 [I; R = CH2NO2, alkyl, (hetero)aryl, (di)(alkyl)amino, etc.; R1 = (un)substituted anilinophenyl, -phenoxyphenyl, -C-attached carbazolyl, etc.; Z = bond or phenylene; Z1 = bond, O, S, NH, CH2NH, CO, CONH, etc.; Z2 = bond, O, NH, oxyalkylene, (heteroatom-interrupted) alkylene, etc.] were prepared Thus,4-(H2N)C6H4NHPh was amidated by Me 2-thiophenethiocarboximidate hydroiodide to give title compound II.HI. Data for biol. activity of I were given.

IT 262447-11-0P 262447-14-3P 262447-40-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-phenylthiopheneimidamides and analogs as NO synthase inhibitors and oxygen scavengers)

RN 262447-11-0 CAPLUS

CN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(phenylamino)phenyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 262447-14-3 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[[(2-methoxy-10H-phenothiazin-1-yl)methyl]amino]ethyl]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 262447-40-5 CAPLUS
CN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(phenylamino)phenyl]- (CA INDEX NAME)



L4 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:210150 CAPLUS
DOCUMENT NUMBER: 132:251067
TITLE: Novel amidine derivatives, their preparation and application as inhibitors of NO synthase and lipid peroxidation, and pharmaceutical compositions containing them
INVENTOR(S): Auvin, Serge; Chabrier de Lassauniere, Pierre-Etienne; Harnett, Jeremiah; Pons, Dominique; Ulibarri, Gerard
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S, Fr.
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000017190	A2	20000330	WO 1999-FR2250	19990922
WO 2000017190	A3	20001026		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2783519	A1	20000324	FR 1998-11868	19980923
FR 2783519	B1	20030124		
CA 2344224	A1	20000330	CA 1999-2344224	19990922
AU 9956314	A	20000410	AU 1999-56314	19990922
AU 766373	B2	20031016		
BR 9913904	A	20010703	BR 1999-13904	19990922
EP 1115719	A2	20010718	EP 1999-943024	19990922
EP 1115719	B1	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
HU 2001003513	A2	20020529	HU 2001-3513	19990922
HU 2001003513	A3	20021028		
JP 2002526493	T	20020820	JP 2000-574099	19990922
AT 233750	T	20030315	AT 1999-943024	19990922
EP 1318149	A1	20030611	EP 2002-26170	19990922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PT 1115719	T	20030731	PT 1999-943024	19990922
NZ 511189	A	20030926	NZ 1999-511189	19990922
ES 2194501	T3	20031116	ES 1999-943024	19990922
RU 2238939	C2	20041027	RU 2001-111022	19990922
IL 141998	A	20050925	IL 1999-141998	19990922
US 6653312	B1	20031125	US 2001-787467	20010316

MX 2001PA03014	A	20000827	MX 2001-PA3014		20010322
NO 2001001479	A	20010518	NO 2001-1479		20010322
KR 746762	B1	20070806	KR 2001-703733		20010323
ZA 2001003204	A	20020919	ZA 2001-3204		20010419
IN 2001MN00425	A	20070706	IN 2001-MN425		20010419
HK 1042486	A1	20050225	HK 2002-103892		20020524
US 2005261269	A1	20051124	US 2003-662183		20030912
IN 2005MN00470	A	20050930	IN 2005-MN470		20050520
US 2006084667	A1	20060420	US 2005-250783		20051014
PRIORITY APPLN. INFO.:			FR 1998-11868	A	19980923
			EP 1999-943024	A3	19990922
			WO 1999-FR2250	W	19990922
			US 2001-787467	A3	20010316
			IN 2001-MN425	A3	20010419
			US 2003-662183	A3	20030912

OTHER SOURCE(S): MARPAT 132:251067

GI



I



II

AB The invention concerns novel amidine derivs., including compds. I [R = H, alkyl, alkoxy; A = certain substituted aryl or (un)substituted heteroaryl groups; B = alkyl, (un)substituted aryl or heteroaryl, (un)substituted or heterocyclic amino; X = bond, (CH2)m, O(CH2)m, (CH2)mO, S(CH2)m, O(CH2)mCO, CH:CH, etc.; Y = bond, (CH2)n, (CH2)rQ(CH2)s; Q = piperazine, homopiperazine, piperidine, pyrrolidine, azetidine, thiazolidine, saturated C3-7 carbocycles, etc; Z = bond, (CH2)pO(CH2)q, (CH2)pS(CH2)q, (CH2)pNH(CH2)q, etc; m, n, p, q, r, s = 0-6], as well as addnl. specific compds. In particular, 2-hydroxy-5-methoxy-N-[2-[4-[(2-thienyliminomethyl)amino]phenyl]ethyl]benzamide (II) and 2,5-dihydroxy-N-[2-[4-[(2-thienyliminomethyl)amino]phenyl]ethyl]benzamide are disclosed. Also disclosed are the use of I as medicines, and pharmaceutical compns. containing them. For instance, amidation of 5-methoxysalicylic acid with 4-nitrophenethylamine-HCl, followed by hydrogenation of the nitro group to amino, condensation of the amine with S-methyl-2-thiophenethiocarboximide-HI, and acidification in acetone, gave II.HCl. The IC50 of selected I, including II.HCl, against rat neuronal NO synthase in vitro, was < 3.5 μM.

IT 262614-47-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of amidine derivs. as inhibitors of NO synthase and/or lipid peroxidn.)
RN 262614-47-1 CAPLUS
CN Carbamic acid, [2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenoxy]ethyl][2-[4-[(imino-2-thienylmethyl)amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 262613-22-9P 262613-23-0P 262613-34-3P
262613-35-4P 262613-36-5P 262613-37-6P
262613-38-7P 262613-39-8P 262613-40-1P
262613-41-2P 262613-42-3P 262613-45-6P
262613-46-7P 262613-47-8P 262613-48-9P
262613-49-0P 262613-54-7P 262613-55-8P
262613-84-3P 262614-21-1P 262614-22-2P
262614-23-3P 262614-24-4P 262614-25-5P
262614-26-6P 262614-27-7P 262614-28-8P
262614-29-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of amidine derivs. as inhibitors of NO synthase and/or lipid peroxidn.)
RN 262613-22-9 CAPLUS
CN Butanamide, 4-[[4-[(imino-2-thienylmethyl)amino]phenyl]amino]-N-[4-[(methylsulfonyl)amino]phenyl]- (CA INDEX NAME)



RN 262613-23-0 CAPLUS
CN Butanamide, N-[4-(dimethylamino)phenyl]-4-[[4-[(imino-2-thienylmethyl)amino]phenyl]amino]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 262613-34-3 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenoxy]ethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 262613-35-4 CAPLUS
CN Carbamic acid, [3-[[4-(dimethylamino)phenyl]amino]-3-oxopropyl][[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 262613-36-5 CAPLUS
CN Propanamide, N-[4-(dimethylamino)phenyl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 262613-37-6 CAPLUS
CN Propanamide, N-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 262613-38-7 CAPLUS
CN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(4-methyl-1-piperazinyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 262613-39-8 CAPLUS
CN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(4-morpholinyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 262613-40-1 CAPLUS
CN Propanamide, N-(2,3-dihydro-1-methyl-1H-indol-5-yl)-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 262613-41-2 CAPLUS
CN Propanamide, N-[2,3-dihydro-1-(phenylmethyl)-1H-indol-5-yl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● HCl

PAGE 1-B

— Ph

RN 262613-42-3 CAPLUS

CN Propanamide, N-[2,3-dihydro-1-(1-naphthalenylmethyl)-1H-indol-5-yl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 262613-45-6 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[[(8-hydroxy-2-quinolinyl)methyl]amino]ethyl]phenyl]- (CA INDEX NAME)



RN 262613-46-7 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[(3-phenyl-2-propenyl)amino]ethyl]phenyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 262613-47-8 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[[3-(4-hydroxy-3-methoxyphenyl)-2-propenyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 262613-48-9 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[[3-(4-hydroxy-3-methoxyphenyl)-2-propenyl]amino]ethyl]phenyl]-, (2E)-2-butenedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 262613-47-8
CMF C23 H25 N3 O2 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 262613-49-0 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[[3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 262613-54-7 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methyl]amino]ethyl]phenyl]- (CA INDEX NAME)



RN 262613-55-8 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[[(2E)-3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenyl]methylamino]ethyl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 262613-84-3 CAPLUS
CN Propanamide, N-[2,3-dihydro-1-(1-naphthalenylmethyl)-1H-indol-5-yl]-3-[[[5-[(imino-2-thienylmethyl)amino]-2-methoxyphenyl]methyl]amino]- (CA INDEX NAME)



RN 262614-21-1 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenoxy]ethyl]amino]ethyl]phenyl]- (CA INDEX NAME)



RN 262614-22-2 CAPLUS
CN Propanamide, N-[4-(dimethylamino)phenyl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]- (CA INDEX NAME)



RN 262614-23-3 CAPLUS
CN Propanamide, N-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]- (CA INDEX NAME)



RN 262614-24-4 CAPLUS
CN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 262614-25-5 CAPLUS
CN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 262614-26-6 CAPLUS
CN Propanamide, N-(2,3-dihydro-1-methyl-1H-indol-5-yl)-3-[[[3-[(imino-2-

thienylmethyl)amino]phenyl]methyl]amino]- (CA INDEX NAME)



RN 262614-27-7 CAPLUS
CN Propanamide, N-[2,3-dihydro-1-(phenylmethyl)-1H-indol-5-yl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Ph

RN 262614-28-8 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[(3-phenyl-2-propenyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 262614-29-9 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[[3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)



```
=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    61.39     241.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -8.80      -8.80

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 07:56:59 ON 16 JAN 2008

Connecting via Winsock to STN



Welcome to STN International!  Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 08:05:42 ON 16 JAN 2008
FILE 'CAPLUS' ENTERED AT 08:05:42 ON 16 JAN 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    61.39     241.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -8.80      -8.80

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    61.87     241.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -8.80      -8.80

FILE 'REGISTRY' ENTERED AT 08:06:04 ON 16 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   14 JAN 2008  HIGHEST RN 960583-85-1
DICTIONARY FILE UPDATES:  14 JAN 2008  HIGHEST RN 960583-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.
```

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10662183\10662183n.str





chain nodes :
1 2 3 4 14 15 16 17 23 30
ring nodes :
5 6 7 8 9 10 24 25 26 27 28 29
chain bonds :
1-2 2-3 2-4 8-14 14-15 15-16 16-17 17-23 28-30
ring bonds :
5-10 5-6 6-7 7-8 8-9 9-10 24-25 24-29 25-26 26-27 27-28 28-29
exact/norm bonds :
1-2 2-3 2-4 16-17 17-23 28-30
exact bonds :
8-14 14-15 15-16
normalized bonds :
5-10 5-6 6-7 7-8 8-9 9-10 24-25 24-29 25-26 26-27 27-28 28-29
isolated ring systems :
containing 5 :

G1:O,S,N

G2:CH2,Hy

Match level :
1:Atom 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
12:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 23:CLASS 24:Atom 25:Atom
26:Atom 27:Atom 28:Atom 29:Atom 30:CLASS

L5   STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5   STR



G1 O,S,N

G2 CH2,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l5
SAMPLE SEARCH INITIATED 08:06:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   17949 TO ITERATE

 11.1% PROCESSED   2000 ITERATIONS   0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 350957 TO   367003
PROJECTED ANSWERS: 0 TO   0

L6   0 SEA SSS SAM L5

=> s l5 full
FULL SEARCH INITIATED 08:06:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 355455 TO ITERATE

91.3% PROCESSED 324580 ITERATIONS 21 ANSWERS

100.0% PROCESSED 355455 ITERATIONS 21 ANSWERS
SEARCH TIME: 00.00.18

L7 21 SEA SSS FUL L5

=> d scan

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, N-[2,3-dihydro-1-(phenylmethyl)-1H-indol-5-yl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-
MF C30 H31 N5 O S
CI COM

PAGE 1-A



PAGE 1-B

— Ph

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):20

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, N-[4-(dimethylamino)phenyl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-
MF C23 H27 N5 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(4-morpholinyl)phenyl]-, monohydrochloride (9CI)
MF C25 H29 N5 O2 S . Cl H



● HCl

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Butanamide, N-[4-(dimethylamino)phenyl]-4-[[4-[(imino-2-thienylmethyl)amino]phenyl]amino]-, hydrochloride (9CI)
MF C23 H27 N5 O S . x Cl H



●x HCl

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, N-[2,3-dihydro-1-(1-naphthalenylmethyl)-1H-indol-5-yl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-
MF C34 H33 N5 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, N-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-
MF C29 H38 N4 O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, N-(2,3-dihydro-1-methyl-1H-indol-5-yl)-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-, monohydrochloride (9CI)
MF C24 H27 N5 O S . Cl H



● HCl

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Carbamic acid, [3-[[4-(dimethylamino)phenyl]amino]-3-oxopropyl][[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI)

MF C28 H35 N5 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Butanamide, N-[4-(dimethylamino)phenyl]-4-[[4-[(imino-2-thienylmethyl)amino]phenyl]amino]-
MF C23 H27 N5 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(4-methyl-1-piperazinyl)phenyl]-
MF C26 H32 N6 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, N-[2,3-dihydro-1-(phenylmethyl)-1H-indol-5-yl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-, monohydrochloride (9CI)
MF C30 H31 N5 O S . Cl H

PAGE 1-A



● HCl

PAGE 1-B

— Ph

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, N-[4-(dimethylamino)phenyl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-, monohydrochloride (9CI)
MF C23 H27 N5 O S . Cl H



● HCl

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(phenylamino)phenyl]-, trihydrochloride (9CI)
MF C27 H27 N5 O S . 3 Cl H



● 3 HCl

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(4-morpholinyl)phenyl]-
MF C25 H29 N5 O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, N-[2,3-dihydro-1-(1-naphthalenylmethyl)-1H-indol-5-yl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-, monohydrochloride (9CI)
MF C34 H33 N5 O S . Cl H



● HCl

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, N-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-, monohydrochloride (9CI)
MF C29 H38 N4 O2 S . Cl H



● HCl

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(phenylamino)phenyl]-
MF C27 H27 N5 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, N-(2,3-dihydro-1-methyl-1H-indol-5-yl)-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-
MF C24 H27 N5 O S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, N-[2,3-dihydro-1-(1-naphthalenylmethyl)-1H-indol-5-yl]-3-[[[5-[(imino-2-thienylmethyl)amino]-2-methoxyphenyl]methyl]amino]-
MF C35 H35 N5 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(4-methyl-1-piperazinyl)phenyl]-, monohydrochloride (9CI)
MF C26 H32 N6 O S . Cl H



● HCl

L7 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Butanamide, 4-[[4-[(imino-2-thienylmethyl)amino]phenyl]amino]-N-[4-[(methylsulfonyl)amino]phenyl]-
MF C22 H25 N5 O3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```
=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     179.28     421.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -8.80

FILE 'CAPLUS' ENTERED AT 08:07:39 ON 16 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 16 Jan 2008  VOL 148 ISS 3
FILE LAST UPDATED: 14 Jan 2008  (20080114/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l7
L8           3 L7

=> d l8 1-3 ibib abs hitstr

L8   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2002:107089  CAPLUS
DOCUMENT NUMBER:         136:167182
TITLE:                   Novel cdc25 phosphatase inhibitors
INVENTOR(S):             Prevost, Gregoire; Brezak Pannetier, Marie-Christine;
                         Galcera Contour, Marie-Odile; Thurieau, Christophe;
                         Goubin-Grammatica, Francoise; Ducommun, Bernard;
                         Lanco, Christophe
PATENT ASSIGNEE(S):      Societe de Conseils de Recherches et d'Applications
                         Scientifiques (SCRAS), Fr.
SOURCE:                  PCT Int. Appl., 92 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                French
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
     WO 2002009686        A2    20020207    WO 2001-FR2443         20010726
     WO 2002009686        A3    20031009
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
```

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

FR 2812198	A1	20020201	FR 2000-9900		20000728
CA 2417262	A1	20020207	CA 2001-2417262		20010726
EP 1370255	A2	20031217	EP 2001-960837		20010726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001012824	A	20040210	BR 2001-12824		20010726
HU 2003003828	A2	20040301	HU 2003-3828		20010726
HU 2003003828	A3	20071029			
JP 2004506618	T	20040304	JP 2002-515239		20010726
NZ 523739	A	20050930	NZ 2001-523739		20010726
EP 1602368	A2	20051207	EP 2005-18614		20010726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR					
RU 2285521	C2	20061020	RU 2003-105689		20010726
NO 2003000421	A	20030319	NO 2003-421		20030127
US 2004034103	A1	20040219	US 2003-343171		20030127
US 7196084	B2	20070327			
MX 2003PA00860	A	20030606	MX 2003-PA860		20030128
US 2006154933	A1	20060713	US 2006-350692		20060209
US 2006235027	A1	20061019	US 2006-410659		20060425
AU 2006233164	A1	20061109	AU 2006-233164		20061024
PRIORITY APPLN. INFO.:			FR 2000-9900	A	20000728
			EP 2001-960837	A3	20010726
			WO 2001-FR2443	W	20010726
			US 2003-343171	A3	20030127

OTHER SOURCE(S): MARPAT 136:167182

AB Novel cdc25 phosphatase inhibitors, particularly cdc25-C inhibitors, A-B-N(W)-X-Y [A = (un)substituted Ph, 2-naphthyl; B = CO, NHCO(CH2)n, (CH2)p; n = 0-3; p = 0, 1; W = H, alkyl; X = (CH2)q, (CH2)qNH, CO(CH2)r; q = 1-6; r = 0-6; N(W)X = (un)substituted diazacycloalkyl; Y = (un)substituted Ph] were prepared Thus, 4-O2NC6H4CH2CH2NMeCH2C6H3(NMe2)OH-5,2 was obtained from 4-O2NC6H4CH2CH2NHMe and 5,2-Me2N(HO)C6H3CHO by reductive alkylation. This compound had an IC50 < 100μM for inhibition of recombinant cdc25-C phosphatase and for inhibition of Mia-Paca2 cell proliferation.

IT 262614-22-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenol and naphthol derivs. as inhibitors of cdc25-C phosphatase)

RN 262614-22-2 CAPLUS

CN Propanamide, N-[4-(dimethylamino)phenyl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]- (CA INDEX NAME)



L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:210152 CAPLUS
DOCUMENT NUMBER: 132:251068
TITLE: Preparation of N-phenylthiopheneimidamides and analogs as NO synthase inhibitors and oxygen scavengers
INVENTOR(S): Bigg, Dennis; Chabrier De Lassauniere, Pierre-Etienne; Auvin, Serge; Harnett, Jeremiah; Ulibarri, Gerard
PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'Applications Scientifiques (S.C.R.A.S, Fr.
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000017191	A2	20000330	WO 1999-FR2251	19990922
WO 2000017191	A3	20001026		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2784678	A1	20000421	FR 1998-11867	19980923
FR 2784678	B1	20021129		
CA 2344223	A1	20000330	CA 1999-2344223	19990922
AU 9956315	A	20000410	AU 1999-56315	19990922
AU 759958	B2	20030501		
BR 9913899	A	20010703	BR 1999-13899	19990922
EP 1115720	A2	20010718	EP 1999-943025	19990922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
HU 2001004013	A2	20020429	HU 2001-4013	19990922
HU 2001004013	A3	20030128		
JP 2003517444	T	20030527	JP 2000-574100	19990922
NZ 511188	A	20030829	NZ 1999-511188	19990922
RU 2230742	C2	20040620	RU 2001-111023	19990922
US 6482822	B1	20021119	US 2001-787466	20010316
NO 2001001478	A	20010322	NO 2001-1478	20010322
MX 2001PA03006	A	20010910	MX 2001-PA3006	20010322
ZA 2001003206	A	20020719	ZA 2001-3206	20010419
IN 2001MN00427	A	20050909	IN 2001-MN427	20010419
HK 1043365	A1	20050107	HK 2002-105058	20020708
US 6620840	B1	20030916	US 2002-255849	20020926
US 2004097494	A1	20040520	US 2003-612646	20030701
US 6809090	B2	20041026		
US 2005027009	A1	20050203	US 2004-895578	20040721
US 2005197329	A1	20050908	US 2005-114803	20050426
US 7186752	B2	20070306		
IN 2005MN00576	A	20051104	IN 2005-MN576	20050607

PRIORITY APPLN. INFO.:

FR 1998-11867	A	19980923
WO 1999-FR2251	W	19990922
US 2001-787466	A3	20010316
IN 2001-MN427	A3	20010419
US 2002-255849	A3	20020926
US 2003-612646	A3	20030701
US 2004-895578	A3	20040721

OTHER SOURCE(S): MARPAT 132:251068

GI



II

AB R1Z1Z2ZNCRNH2 [I; R = CH2NO2, alkyl, (hetero)aryl, (di)(alkyl)amino, etc.; R1 = (un)substituted anilinophenyl, -phenoxyphenyl, -C-attached carbazolyl, etc.; Z = bond or phenylene; Z1 = bond, O, S, NH, CH2NH, CO, CONH, etc.; Z2 = bond, O, NH, oxyalkylene, (heteroatom-interrupted) alkylene, etc.] were prepared Thus,4-(H2N)C6H4NHPh was amidated by Me 2-thiophenethiocarboximidate hydroiodide to give title compound II.HI. Data for biol. activity of I were given.

IT 262447-11-0P 262447-40-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-phenylthiopheneimidamides and analogs as NO synthase inhibitors and oxygen scavengers)

RN 262447-11-0 CAPLUS

CN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(phenylamino)phenyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 262447-40-5 CAPLUS

CN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(phenylamino)phenyl]- (CA INDEX NAME)



L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:210150 CAPLUS

DOCUMENT NUMBER: 132:251067

TITLE: Novel amidine derivatives, their preparation and application as inhibitors of NO synthase and lipid peroxidation, and pharmaceutical compositions containing them

INVENTOR(S): Auvin, Serge; Chabrier de Lassauniere, Pierre-Etienne; Harnett, Jeremiah; Pons, Dominique; Ulibarri, Gerard

PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S, Fr.

SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000017190	A2	20000330	WO 1999-FR2250	19990922
WO 2000017190	A3	20001026		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2783519	A1	20000324	FR 1998-11868	19980923
FR 2783519	B1	20030124		
CA 2344224	A1	20000330	CA 1999-2344224	19990922
AU 9956314	A	20000410	AU 1999-56314	19990922
AU 766373	B2	20031016		
BR 9913904	A	20010703	BR 1999-13904	19990922
EP 1115719	A2	20010718	EP 1999-943024	19990922
EP 1115719	B1	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
HU 2001003513	A2	20020529	HU 2001-3513	19990922
HU 2001003513	A3	20021028		
JP 2002526493	T	20020820	JP 2000-574099	19990922
AT 233750	T	20030315	AT 1999-943024	19990922
EP 1318149	A1	20030611	EP 2002-26170	19990922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PT 1115719	T	20030731	PT 1999-943024	19990922
NZ 511189	A	20030926	NZ 1999-511189	19990922
ES 2194501	T3	20031116	ES 1999-943024	19990922
RU 2238939	C2	20041027	RU 2001-111022	19990922
IL 141998	A	20050925	IL 1999-141998	19990922
US 6653312	B1	20031125	US 2001-787467	20010316
MX 2001PA03014	A	20000827	MX 2001-PA3014	20010322
NO 2001001479	A	20010518	NO 2001-1479	20010322
KR 746762	B1	20070806	KR 2001-703733	20010323
ZA 2001003204	A	20020919	ZA 2001-3204	20010419
IN 2001MN00425	A	20070706	IN 2001-MN425	20010419
HK 1042486	A1	20050225	HK 2002-103892	20020524
US 2005261269	A1	20051124	US 2003-662183	20030912
IN 2005MN00470	A	20050930	IN 2005-MN470	20050520
US 2006084667	A1	20060420	US 2005-250783	20051014

PRIORITY APPLN. INFO.:

FR 1998-11868	A	19980923
EP 1999-943024	A3	19990922
WO 1999-FR2250	W	19990922
US 2001-787467	A3	20010316
IN 2001-MN425	A3	20010419
US 2003-662183	A3	20030912

OTHER SOURCE(S): MARPAT 132:251067

GI



I



II

AB The invention concerns novel amidine derivs., including compds. I [R = H, alkyl, alkoxy; A = certain substituted aryl or (un)substituted heteroaryl groups; B = alkyl, (un)substituted aryl or heteroaryl, (un)substituted or heterocyclic amino; X = bond, (CH2)m, O(CH2)m, (CH2)mO, S(CH2)m, O(CH2)mCO, CH:CH, etc.; Y = bond, (CH2)n, (CH2)rQ(CH2)s; Q = piperazine, homopiperazine, piperidine, pyrrolidine, azetidine, thiazolidine, saturated C3-7 carbocycles, etc; Z = bond, (CH2)pO(CH2)q, (CH2)pS(CH2)q, (CH2)pNH(CH2)q, etc; m, n, p, q, r, s = 0-6], as well as addnl. specific compds. In particular, 2-hydroxy-5-methoxy-N-[2-[4-[(2-thienyliminomethyl)amino]phenyl]ethyl]benzamide (II) and 2,5-dihydroxy-N-[2-[4-[(2-thienyliminomethyl)amino]phenyl]ethyl]benzamide are disclosed. Also disclosed are the use of I as medicines, and pharmaceutical compns. containing them. For instance, amidation of 5-methoxysalicylic acid with 4-nitrophenethylamine-HCl, followed by hydrogenation of the nitro group to amino, condensation of the amine with S-methyl-2-thiophenethiocarboximide-HI, and acidification in acetone, gave II.HCl. The IC50 of selected I, including II.HCl, against rat neuronal NO synthase in vitro, was < 3.5 μM.

IT 262613-22-9P 262613-23-0P 262613-35-4P
262613-36-5P 262613-37-6P 262613-38-7P
262613-39-8P 262613-40-1P 262613-41-2P
262613-42-3P 262613-84-3P 262614-22-2P
262614-23-3P 262614-24-4P 262614-25-5P
262614-26-6P 262614-27-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of amidine derivs. as inhibitors of NO synthase
and/or lipid peroxidn.)

RN 262613-22-9 CAPLUS

CN Butanamide, 4-[[4-[(imino-2-thienylmethyl)amino]phenyl]amino]-N-[4-[(methylsulfonyl)amino]phenyl]- (CA INDEX NAME)



RN 262613-23-0 CAPLUS
CN Butanamide, N-[4-(dimethylamino)phenyl]-4-[[4-[(imino-2-thienylmethyl)amino]phenyl]amino]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 262613-35-4 CAPLUS
CN Carbamic acid, [3-[[4-(dimethylamino)phenyl]amino]-3-oxopropyl][[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 262613-36-5 CAPLUS
CN Propanamide, N-[4-(dimethylamino)phenyl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 262613-37-6 CAPLUS

CN Propanamide, N-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 262613-38-7 CAPLUS
CN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(4-methyl-1-piperazinyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 262613-39-8 CAPLUS
CN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(4-morpholinyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 262613-40-1 CAPLUS
CN Propanamide, N-(2,3-dihydro-1-methyl-1H-indol-5-yl)-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 262613-41-2 CAPLUS
CN Propanamide, N-[2,3-dihydro-1-(phenylmethyl)-1H-indol-5-yl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● HCl

PAGE 1-B

— Ph

RN 262613-42-3 CAPLUS
CN Propanamide, N-[2,3-dihydro-1-(1-naphthalenylmethyl)-1H-indol-5-yl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 262613-84-3 CAPLUS
CN Propanamide, N-[2,3-dihydro-1-(1-naphthalenylmethyl)-1H-indol-5-yl]-3-[[[5-[(imino-2-thienylmethyl)amino]-2-methoxyphenyl]methyl]amino]- (CA INDEX NAME)



RN 262614-22-2 CAPLUS
CN Propanamide, N-[4-(dimethylamino)phenyl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]- (CA INDEX NAME)



RN 262614-23-3 CAPLUS
CN Propanamide, N-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]- (CA INDEX NAME)



RN 262614-24-4 CAPLUS
CN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 262614-25-5 CAPLUS
CN Propanamide, 3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 262614-26-6 CAPLUS
CN Propanamide, N-(2,3-dihydro-1-methyl-1H-indol-5-yl)-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]- (CA INDEX NAME)



RN 262614-27-7 CAPLUS
CN Propanamide, N-[2,3-dihydro-1-(phenylmethyl)-1H-indol-5-yl]-3-[[[3-[(imino-2-thienylmethyl)amino]phenyl]methyl]amino]- (CA INDEX NAME)



— Ph

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	17.31	438.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.40	-11.20

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 08:08:49 ON 16 JAN 2008